Tanezumab

Summary

Tanezumab (CHEMBL2108567) is a phase-3 clinical-stage antibody (ATC N02BG12); indicated across 13 conditions including osteoarthritis, hip and osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: N02BG12
• Indications: 13 conditions
• Clinical trials: 32

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108567
Name	Tanezumab
Type	Antibody
Max phase	3
ATC	N02BG12

Also known as: PF-04383119, PF-4383119, RN-624, RN624, Tanezumab, TANEZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

13 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, hip	3	MONDO:0006629	EFO:1000786
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616
osteoarthritis	3	MONDO:0005178	MONDO:0005178
endometriosis	2	MONDO:0005133	EFO:0001065
chronic pancreatitis	2	MONDO:0005003	EFO:0000342
prostatitis	2	MONDO:0005280	EFO:0003830
interstitial cystitis	2	MONDO:0018301	EFO:1000869
diabetic neuropathy	2	MONDO:0006626	EFO:1000783

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 32.

Phase distribution

Phase	Trials
PHASE3	16
PHASE2	14
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00733902	PHASE3	COMPLETED	Tanezumab in Osteoarthritis of the Knee
NCT00744471	PHASE3	COMPLETED	Tanezumab in Osteoarthritis Of The Hip
NCT00809354	PHASE3	TERMINATED	Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
NCT00809783	PHASE3	TERMINATED	Extension Study Of Tanezumab In Osteoarthritis
NCT00830063	PHASE3	COMPLETED	Tanezumab In Osteoarthritis Of The Knee (2)
NCT00863304	PHASE3	COMPLETED	Tanezumab in Osteoarthritis of the Hip or Knee (2)
NCT00863772	PHASE3	TERMINATED	Tanezumab and Nerve Function In Arthritis Patients
NCT00864097	PHASE3	TERMINATED	Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip
NCT00960804	PHASE3	TERMINATED	Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
NCT00985621	PHASE3	TERMINATED	Tanezumab In Osteoarthritis Of The Hip Or Knee
NCT01127893	PHASE3	TERMINATED	Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis
NCT02528188	PHASE3	COMPLETED	Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
NCT02609828	PHASE3	COMPLETED	Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
NCT02697773	PHASE3	COMPLETED	Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
NCT02709486	PHASE3	COMPLETED	Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
NCT02725411	PHASE3	COMPLETED	Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
NCT00394563	PHASE2	COMPLETED	A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
NCT00399490	PHASE2	COMPLETED	Open-label Extension Study Of RN624
NCT00568321	PHASE2	COMPLETED	RN624 For Pain Of Post-Herpetic Neuralgia
NCT00584870	PHASE2	COMPLETED	RN624 In Adult Patients With Chronic Low Back Pain
NCT00601484	PHASE2	COMPLETED	An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
NCT00669409	PHASE2	COMPLETED	A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee
NCT00784693	PHASE2	TERMINATED	A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
NCT00826514	PHASE2	COMPLETED	An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
NCT00924664	PHASE2	TERMINATED	Long Term Safety Study of Tanezumab in Chronic Low Back Pain
NCT00994890	PHASE2	TERMINATED	A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
NCT00999518	PHASE2	TERMINATED	A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
NCT01087203	PHASE2	TERMINATED	A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
NCT01146561	PHASE2	TERMINATED	Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis
NCT04163419	PHASE2	UNKNOWN	Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
NCT00788294	PHASE1	COMPLETED	Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
NCT01030640	PHASE1	COMPLETED	Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).